After the U.S. President received an experimental treatment from Regeneron (NASDAQ:REGN), buying interest picked up for the stock. The anti-viral treatment, in the form of two proteins, is an unexpected catalyst for the drug company.

Regeneron derives much of its revenue from the blockbuster drug, Dupixent. Still, the price-to-earnings may expand if investors believe its Covid-19 drug could save many lives.

On the vaccine side, Moderna (NASDAQ:MRNA) continued to rebound in recent months. The company is filling up enrollment for 30,000 subjects. As it shares the data read-out, markets may grow increasingly bullish on its prospects. The company said at a Financial Times conference that it would not apply for emergency use authorization for its vaccine, mRNA-1273, before Nov. 25. So, investors cannot predict yet when Moderna may forecast revenue growth for its core product.

BioNTech (NASDAQ:BNTX) is getting closer to breaking out as it seeks approval of its vaccine candidate, BNT162b2. The company said it started the rolling submission to the European Medicines Agency to start a rolling review. Given the encouraging preliminary results, BNTX and Pfizer (NYSE:PFE) have a good chance of bringing their vaccine to market. As orders increase, investors may forecast future revenue and assign a higher value to the stock.